Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:14 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:14 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $83.79, denoting a -0.24% change from the preceding trading day.
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
by Zacks Equity Research
AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
by Zacks Equity Research
Gilead Sciences and Nuvalent are in the spotlight following positive updates on key candidates.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
by Zacks Equity Research
GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) reachead $81.01 at the closing of the latest trading day, reflecting a -0.53% change compared to its last close.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Why Biotech ETFs Are Beating the Market
by Neena Mishra
: Biotech stocks are poised to benefit from lower rates
Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for COWZ
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
by Zacks Equity Research
While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.
Is Pacer US Cash Cows 100 ETF (COWZ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for COWZ
Top Stock Reports for Texas Instruments, Union Pacific & Vertex Pharmaceuticals
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Incorporated (TXN), Union Pacific Corporation (UNP) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks Tile Shop Holdings, Inc. (TTSH) and Gencor Industries, Inc. (GENC).
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
by Zacks Equity Research
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
by Ekta Bagri
Bigwigs Regeneron (REGN) and Gilead Sciences (GILD) are in the spotlight following regulatory updates and drug approval, respectively.
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
by Zacks Equity Research
Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.
Bristol Myers (BMY) Gains 16% in a Month: Should You Buy or Wait?
by Ekta Bagri
Bristol Myers' (BMY) impressive second-quarter results propelled the stock in the past month. However, we advise investors not to be over-optimistic at this point and look before they leap.
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.
Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 24.84% and 4.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Continuing Claims Hit Highest Since Nov 2021
by Zacks Equity Research
Continuing Claims Hit Highest Since Nov 2021
Jobless Claims Decline, Pre-Markets in the Green
by Zacks Equity Research
It???s a big day for Wall Street as the much-awaited Jobless Claims numbers are out, which could be a major factor in market moves for the rest of the week.
2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 17.14% and 21.55%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?